Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.15
IART's Cash-to-Debt is ranked lower than
90% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. IART: 0.15 )
Ranked among companies with meaningful Cash-to-Debt only.
IART' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.32 Max: No Debt
Current: 0.15
Equity-to-Asset 0.46
IART's Equity-to-Asset is ranked lower than
68% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. IART: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
IART' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.53 Max: 0.93
Current: 0.46
0.32
0.93
Interest Coverage 4.47
IART's Interest Coverage is ranked lower than
87% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: 93.54 vs. IART: 4.47 )
Ranked among companies with meaningful Interest Coverage only.
IART' s Interest Coverage Range Over the Past 10 Years
Min: 1.58  Med: 3.35 Max: 5.38
Current: 4.47
1.58
5.38
Piotroski F-Score: 8
Altman Z-Score: 3.16
Beneish M-Score: -2.50
WACC vs ROIC
6.37%
6.58%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 11.63
IART's Operating Margin % is ranked higher than
75% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. IART: 11.63 )
Ranked among companies with meaningful Operating Margin % only.
IART' s Operating Margin % Range Over the Past 10 Years
Min: 5.08  Med: 8.95 Max: 14.33
Current: 11.63
5.08
14.33
Net Margin % 7.34
IART's Net Margin % is ranked higher than
71% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. IART: 7.34 )
Ranked among companies with meaningful Net Margin % only.
IART' s Net Margin % Range Over the Past 10 Years
Min: -3.02  Med: 4.62 Max: 8.97
Current: 7.34
-3.02
8.97
ROE % 9.13
IART's ROE % is ranked higher than
69% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 2.08 vs. IART: 9.13 )
Ranked among companies with meaningful ROE % only.
IART' s ROE % Range Over the Past 10 Years
Min: -3.56  Med: 8.46 Max: 13.9
Current: 9.13
-3.56
13.9
ROA % 4.02
IART's ROA % is ranked higher than
66% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. IART: 4.02 )
Ranked among companies with meaningful ROA % only.
IART' s ROA % Range Over the Past 10 Years
Min: -1.79  Med: 3.29 Max: 6.71
Current: 4.02
-1.79
6.71
ROC (Joel Greenblatt) % 23.99
IART's ROC (Joel Greenblatt) % is ranked higher than
72% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 4.02 vs. IART: 23.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IART' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 8.48  Med: 17.62 Max: 32.36
Current: 23.99
8.48
32.36
3-Year Revenue Growth Rate 1.20
IART's 3-Year Revenue Growth Rate is ranked lower than
63% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. IART: 1.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IART' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -5.3  Med: 15.8 Max: 55
Current: 1.2
-5.3
55
3-Year EBITDA Growth Rate 25.50
IART's 3-Year EBITDA Growth Rate is ranked higher than
77% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. IART: 25.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IART' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -38  Med: 10.35 Max: 35.1
Current: 25.5
-38
35.1
3-Year EPS without NRI Growth Rate 35.20
IART's 3-Year EPS without NRI Growth Rate is ranked higher than
83% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. IART: 35.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IART' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.2  Med: 0 Max: 35.2
Current: 35.2
-48.2
35.2
GuruFocus has detected 4 Warning Signs with Integra Lifesciences Holdings Corp $IART.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IART's 10-Y Financials

Financials (Next Earnings Date: 2017-05-23 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

IART Guru Trades in Q1 2016

Paul Tudor Jones 3,442 sh (New)
David Dreman 22,258 sh (New)
Steven Cohen 435,400 sh (+7.48%)
Ken Fisher 544,895 sh (-1.32%)
Richard Snow 217,125 sh (-27.39%)
Jim Simons 33,330 sh (-35.07%)
» More
Q2 2016

IART Guru Trades in Q2 2016

RS Investment Management 709,503 sh (New)
Jim Simons 102,530 sh (+207.62%)
David Dreman Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 503,365 sh (-7.62%)
Richard Snow 174,405 sh (-19.68%)
Steven Cohen 258,400 sh (-40.65%)
» More
Q3 2016

IART Guru Trades in Q3 2016

Paul Tudor Jones 8,005 sh (New)
Ken Fisher 526,405 sh (+4.58%)
Steven Cohen 100,000 sh (unchged)
Steven Cohen Sold Out
Richard Snow 146,930 sh (-15.75%)
Jim Simons 19,030 sh (-81.44%)
» More
Q4 2016

IART Guru Trades in Q4 2016

Joel Greenblatt 11,704 sh (New)
Steven Cohen 100,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 521,330 sh (-0.96%)
Richard Snow 66,070 sh (-55.03%)
» More
» Details

Insider Trades

Latest Guru Trades with IART

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:WMGI, OTCPK:GGNDF, NYSE:GMED, OTCPK:EKTAY, NYSE:NVRO, NYSE:PEN, NAS:NUVA, OTCPK:FSPKF, NAS:LIVN, NAS:ZLTQ, OTCPK:NHNKY, NAS:MASI, OTCPK:IOBCF, NAS:CYNO, NAS:INGN, OTCPK:SHHPF, NAS:BABY, NYSE:ITGR, NAS:SPNC, NAS:CNMD » details
Traded in other countries:IL3.Germany,
Integra Lifesciences Holdings Corp is engaged in the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments.

Integra Lifesciences Holdings Corp was incorporated in Delaware in 1989. The Company develops, manufactures and market cost-effective surgical implants and medical instruments. Its products are used mainly in neurosurgery, extremity reconstruction, orthopedics and general surgery. The Company sells its products directly through various sales forces and through various distribution channels. The Company currently manufactures and sells its products in five reportable business segments: U.S. Neurosurgery, U.S. Extremities, U.S. Instruments, U.S. Spine and Other, and International. Its U.S. Neurosurgery sales organization sells a full line of products specifically for neurosurgery and neuro critical care. The Company has products for each step of a cranial procedure and the care of the patient after surgery. Its key products include dural repair products, tissue ablation equipment, intracranial monitoring equipment, cranial stabilization equipment, and cerebral spinal fluid management devices. It sells equipment used in the neurosurgery operating room and neurosurgery intensive care unit. It sells its products through directly employed sales representatives. U.S. Extremities; the Company define extremity reconstruction to mean the repair of soft tissue and the orthopedic reconstruction of bone in the foot, ankle and leg below the knee, and the hand, wrist, elbow and shoulder. Its key products include bone and joint fixation devices, implants and instruments for osteoarthritis, rheumatoid arthritis, wrist and shoulder arthroplasty, carpal tunnel syndrome, and cubital tunnel syndrome. Other key products include its regenerative medicine devices for the treatment of acute and chronic wounds, peripheral nerve repair and protection and tendon repair, and bone graft substitutes. The Company sells its products through a direct sales organization and through specialty distributors focused on their respective surgical disciplines. Its U.S. Instruments business portfolio includes over 60,000 instrument patterns and surgical products, including hospitals, surgery centers, and physician, dental and veterinary offices. In addition to selling hand-held instruments, it sells surgical headlight systems and table-mounted retractors. Its brands includes Jarit, Miltex, Padgett, Ruggles, Luxtec and Omni-Tract. The Company's U.S. Spine and Other segment offers comprehensive spinal fusion technologies that surgeons use along the full length of the spine, as well as differentiated offering of related orthobiologics. This segment also includes private-label sales of a broad set of its regenerative medicine technologies. The International segment sells similar products, but they are managed through Europe, Middle East and Africa, Latin/South America, Asia-Pacific, Australia, New Zealand and Canada. The Company's trademarks include AccuDrain, Accell, Accell Evo3, Advansys, Atoll , Ascension, Bold, Budde, Buzz , Camino, CRW, Coral, CUSA, Daytona, DenLite, Dur

Ratios

vs
industry
vs
history
PE Ratio 46.46
IART's PE Ratio is ranked lower than
71% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 27.89 vs. IART: 46.46 )
Ranked among companies with meaningful PE Ratio only.
IART' s PE Ratio Range Over the Past 10 Years
Min: 15.26  Med: 32.27 Max: 6446
Current: 46.46
15.26
6446
Forward PE Ratio 22.27
IART's Forward PE Ratio is ranked higher than
54% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 23.04 vs. IART: 22.27 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 46.46
IART's PE Ratio without NRI is ranked lower than
72% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 28.39 vs. IART: 46.46 )
Ranked among companies with meaningful PE Ratio without NRI only.
IART' s PE Ratio without NRI Range Over the Past 10 Years
Min: 15.16  Med: 32.9 Max: 478.11
Current: 46.46
15.16
478.11
Price-to-Owner-Earnings 38.64
IART's Price-to-Owner-Earnings is ranked lower than
63% of the 102 Companies
in the Global Medical Devices industry.

( Industry Median: 30.77 vs. IART: 38.64 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
IART' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.2  Med: 27 Max: 4303
Current: 38.64
8.2
4303
PB Ratio 3.81
IART's PB Ratio is ranked lower than
55% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.35 vs. IART: 3.81 )
Ranked among companies with meaningful PB Ratio only.
IART' s PB Ratio Range Over the Past 10 Years
Min: 1.21  Med: 2.35 Max: 5.46
Current: 3.81
1.21
5.46
PS Ratio 3.40
IART's PS Ratio is ranked lower than
51% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.31 vs. IART: 3.40 )
Ranked among companies with meaningful PS Ratio only.
IART' s PS Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.79 Max: 4.6
Current: 3.4
0.79
4.6
Price-to-Free-Cash-Flow 49.30
IART's Price-to-Free-Cash-Flow is ranked lower than
72% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 29.73 vs. IART: 49.30 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
IART' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.16  Med: 24.82 Max: 114.67
Current: 49.3
6.16
114.67
Price-to-Operating-Cash-Flow 29.11
IART's Price-to-Operating-Cash-Flow is ranked lower than
65% of the 139 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. IART: 29.11 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IART' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.37  Med: 18.21 Max: 31.04
Current: 29.11
5.37
31.04
EV-to-EBIT 32.35
IART's EV-to-EBIT is ranked lower than
66% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 23.96 vs. IART: 32.35 )
Ranked among companies with meaningful EV-to-EBIT only.
IART' s EV-to-EBIT Range Over the Past 10 Years
Min: -149.8  Med: 22.4 Max: 49.8
Current: 32.35
-149.8
49.8
EV-to-EBITDA 19.91
IART's EV-to-EBITDA is ranked lower than
58% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 17.54 vs. IART: 19.91 )
Ranked among companies with meaningful EV-to-EBITDA only.
IART' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.1  Med: 15.3 Max: 41.5
Current: 19.91
8.1
41.5
PEG Ratio 11.07
IART's PEG Ratio is ranked lower than
83% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 2.47 vs. IART: 11.07 )
Ranked among companies with meaningful PEG Ratio only.
IART' s PEG Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.54 Max: 412.16
Current: 11.07
0.02
412.16
Shiller PE Ratio 75.27
IART's Shiller PE Ratio is ranked lower than
70% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 54.18 vs. IART: 75.27 )
Ranked among companies with meaningful Shiller PE Ratio only.
IART' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.3  Med: 37.95 Max: 187.83
Current: 75.27
17.3
187.83
Current Ratio 4.01
IART's Current Ratio is ranked higher than
74% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. IART: 4.01 )
Ranked among companies with meaningful Current Ratio only.
IART' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 4.22 Max: 13.25
Current: 4.01
0.81
13.25
Quick Ratio 2.25
IART's Quick Ratio is ranked higher than
61% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. IART: 2.25 )
Ranked among companies with meaningful Quick Ratio only.
IART' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 2.63 Max: 12.25
Current: 2.25
0.46
12.25
Days Inventory 228.10
IART's Days Inventory is ranked lower than
75% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 125.58 vs. IART: 228.10 )
Ranked among companies with meaningful Days Inventory only.
IART' s Days Inventory Range Over the Past 10 Years
Min: 194.11  Med: 211.58 Max: 247.25
Current: 228.1
194.11
247.25
Days Sales Outstanding 54.52
IART's Days Sales Outstanding is ranked higher than
68% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. IART: 54.52 )
Ranked among companies with meaningful Days Sales Outstanding only.
IART' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.48  Med: 54.95 Max: 68.65
Current: 54.52
50.48
68.65
Days Payable 30.38
IART's Days Payable is ranked lower than
78% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. IART: 30.38 )
Ranked among companies with meaningful Days Payable only.
IART' s Days Payable Range Over the Past 10 Years
Min: 30.38  Med: 37.24 Max: 66.27
Current: 30.38
30.38
66.27

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.20
IART's 3-Year Average Share Buyback Ratio is ranked lower than
56% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. IART: -5.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IART' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.8  Med: -3.3 Max: 3.1
Current: -5.2
-18.8
3.1

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.16
IART's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
66% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. IART: 3.16 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
IART' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.66  Med: 1.61 Max: 3.17
Current: 3.16
0.66
3.17
Price-to-Median-PS-Value 1.90
IART's Price-to-Median-PS-Value is ranked lower than
86% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 1.07 vs. IART: 1.90 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IART' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59  Med: 1.58 Max: 4.56
Current: 1.9
0.59
4.56
Price-to-Peter-Lynch-Fair-Value 8.32
IART's Price-to-Peter-Lynch-Fair-Value is ranked lower than
96% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 1.68 vs. IART: 8.32 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
IART' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.55  Med: 1.47 Max: 8.35
Current: 8.32
0.55
8.35
Earnings Yield (Greenblatt) % 3.09
IART's Earnings Yield (Greenblatt) % is ranked higher than
69% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: -0.81 vs. IART: 3.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IART' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2  Med: 4.4 Max: 8.4
Current: 3.09
2
8.4
Forward Rate of Return (Yacktman) % 6.92
IART's Forward Rate of Return (Yacktman) % is ranked lower than
59% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 9.01 vs. IART: 6.92 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
IART' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -7.9  Med: 20.6 Max: 1213.4
Current: 6.92
-7.9
1213.4

More Statistics

Revenue (TTM) (Mil) $992.1
EPS (TTM) $ 0.92
Beta0.66
Short Percentage of Float15.58%
52-Week Range $31.79 - 45.87
Shares Outstanding (Mil)74.82

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 1,130 1,226
EPS ($) 1.93 2.20
EPS without NRI ($) 1.93 2.20
EPS Growth Rate
(Future 3Y To 5Y Estimate)
13.00%
Dividends per Share ($)
» More Articles for IART

Headlines

Articles On GuruFocus.com
SeaSpine: A Pure-Play Medical Spinoff Jul 22 2015 
WEEKLY CFO SELLS HIGHLIGHT: LMT, WCG, GRPN, IART, CNK Aug 26 2013 
Integra LifeSciences Holdings Corp. (IART) EVP, Finance & Admin & CFO John B Iii Henneman sells 10,0 Mar 09 2011 
Integra LifeSciences Holdings Corp. (IART) CEO Stuart Essig sells 125,100 Shares Mar 08 2011 
Integra LifeSciences Holdings Corp. (IART) EVP, Finance & Admin & CFO John B Iii Henneman sells 5,32 Dec 08 2010 
Integra LifeSciences Holdings Corp. (IART) CEO Stuart Essig sells 100,000 Shares Dec 03 2010 
Integra LifeSciences Holdings Corp. (IART) CEO Stuart Essig sells 100,000 Shares Nov 04 2010 
Integra LifeSciences Holdings Corp. (IART) EVP, Finance & Admin & CFO John B Iii Henneman sells 100, Nov 04 2010 
Integra LifeSciences Holdings Corp. Reports Operating Results (10-Q) Oct 28 2010 
Integra LifeSciences Holdings Corp. Reports Operating Results (10-Q) Jul 29 2010 

More From Other Websites
Integra LifeSciences Holdings Corp. breached its 50 day moving average in a Bullish Manner : IART-US... Mar 20 2017
Post Earnings Coverage as Cooper's Quarterly Revenue Grew 11%; EPS Surged 46% Mar 17 2017
Integra (IART) Titan Reverse Launch Expands Extremity Line Mar 16 2017
Integra LifeSciences Introduces Next Generation CUSA® Clarity Ultrasonic Tissue Ablation System Mar 16 2017
Integra LifeSciences Introduces Next Generation CUSA® Clarity Ultrasonic Tissue Ablation System Mar 16 2017
Integra LifeSciences Launches Press-Fit Reverse Shoulder for Fracture for the Titan™ Modular... Mar 15 2017
Integra LifeSciences Holdings Corp. breached its 50 day moving average in a Bearish Manner : IART-US... Mar 07 2017
INTEGRA LIFESCIENCES HOLDINGS CORP Financials Mar 01 2017
Integra LifeSciences to Present at the Barclays Global Healthcare Conference and Oppenheimer’s... Feb 28 2017
Integra LifeSciences Holdings Corp. :IART-US: Earnings Analysis: 2016 By the Numbers : February 27,... Feb 27 2017
Integra (IART) Posts In-Line Q4 Earnings, Issues 2017 View Feb 27 2017
Integra LifeSciences Holdings Corp. :IART-US: Earnings Analysis: Q4, 2016 By the Numbers : February... Feb 24 2017
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Completion of Acquisition or Disposition of... Feb 24 2017
Edited Transcript of IART earnings conference call or presentation 23-Feb-17 1:30pm GMT Feb 23 2017
Integra meets 4Q profit forecasts Feb 23 2017
Integra meets 4Q profit forecasts Feb 23 2017
Integra LifeSciences Announces Acceptance of Shares Tendered into Offer for Derma Sciences, Inc. Feb 23 2017
INTEGRA LIFESCIENCES HOLDINGS CORP Files SEC form 8-K, Results of Operations and Financial... Feb 23 2017
Q4 2016 Integra LifeSciences Holdings Corp Earnings Release - Before Market Open Feb 23 2017
Integra LifeSciences Reports Fourth Quarter and Full-Year 2016 Financial Results and Updates 2017... Feb 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)